Linda van de Winkel

Intestinal‐type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment

F. Hoebers, V. Tjan-Heijnen, P. Slootweg, 2016, Head & neck.

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry

L. Kooreman, M. Pepels, V. Tjan-Heijnen, 2022, Breast Cancer Research and Treatment.

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry

M. Pepels, M. de Boer, V. Tjan-Heijnen, 2021, Breast Cancer Research and Treatment.

Prospective cohort study of patients with advanced cancer and their relatives on the experienced quality of care and life (eQuiPe study): a study protocol

M. Pepels, L. van Zuylen, C. Pitz, 2020, BMC Palliative Care.

Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry

M. Pepels, V. Tjan-Heijnen, F. Erdkamp, 2023, The Lancet regional health. Europe.

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

M. Pepels, V. Tjan-Heijnen, F. Erdkamp, 2023, Breast Cancer Research and Treatment.

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry

M. Pepels, M. de Boer, V. Tjan-Heijnen, 2021, International Journal of Cancer.